Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Next-generation CD19-UCART for Relapsed/Refractory B-cell Malignancies
NCT05381181Phase 1Not yet recruiting
- Sponsor
- BRL Medicine Inc.
- Start
- Dec 2023
- Primary completion
- May 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of BRL-301 in acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL), sponsored by BRL Medicine Inc. Primary endpoint: Dose Limiting Toxicities incidence. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
BRL-301
03
Conditions
acute lymphoblastic leukemia (ALL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05381181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05381181.